Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Pulmonx Corporation (NASDAQ: LUNG - Get Free Report) has received an average recommendation of "Hold" from the eight research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.33 per share a year ago.
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Corporation ( LUNG ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Glendon French - CEO, President & Director Derrick Sung - CFO & COO Conference Call Participants Dorothy Morgan - Gilmartin Group LLC Nathan Treybeck - Wells Fargo Securities, LLC, Research Division John Young - Canaccord Genuity Corp., Research Division Jason Bednar - Piper Sandler & Co., Research Division Presentation Dorothy Morgan Gilmartin Group LLC Good afternoon, and thank you for participating in today's call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Operating Officer and Chief Financial Officer.
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.36 per share a year ago.
Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 AM ET Company Participants Mehul Joshi - Chief Financial Officer Steven S. Williamson - CEO, President & Director Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Frederick Allen Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Jeremy Feffer - Lifesci Advisors, LLC Operator Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx Second Quarter 2025 Financial Results Conference Call.
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.
Pulmonx Corporation (NASDAQ:LUNG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Laine Morgan - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.